article thumbnail

ASCO 2025: Vepdegestrant Shows Superiority to Fulvestrant in ER+/HER2- Advanced Breast Cancer

Pharmacy Times

The findings were presented at the 2025 American Society of Clinical Oncology Annual Meeting, which was held in Chicago, Illinois. The findings were presented at the 2025 American Society of Clinical Oncology Annual Meeting, which was held in Chicago, Illinois.

article thumbnail

STAT+: Make America Healthy Again is ringing through statehouses across the U.S.

STAT

From cancer warning labels to soda taxes , progressive states like California and New York have long led the way on legislation meant to improve public health. You’re reading The MAHA Diagnosis , a STAT series that examines the major elements of the Make America Healthy Again movement led by Robert F. Kennedy Jr.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Europe’s pharmaceutical packaging market to value over $35bn by 2028

European Pharmaceutical Review

Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 billion in 2028, according to a report by Arizton. billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 percent up to 2028. percent in 2022.

article thumbnail

Merck’s Welireg becomes first drug for rare VHL tumours in US

pharmaphorum

The drug is part of Merck’s efforts to expand its oncology portfolio and reduce its reliance on big-selling cancer immunotherapy Keytruda (pembrolizumab), which is patent protected in the US and Europe until 2028.

article thumbnail

CD19 CAR-T agents to boost blood cancer market

European Pharmaceutical Review

Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively. This allows for a large total eligible patient population despite capturing less patient share relative to other CD19 CAR-T agents.

article thumbnail

High risk, high reward – the future of CAR-T therapy in CLL

Pharmaceutical Technology

According to GlobalData’s analyst consensus forecast, Yescarta is expected to reach peak sales of $1.8bn in 2028, and Kymriah is expected to reach sales of $686m in the same year. Autologous CAR-T agents are now becoming the standard of care for patients in the third line and later settings, providing lucrative returns for these agents.

article thumbnail

#ASH22: Pirtobrutinib emerges as an option for Richter’s Transformation

Pharmaceutical Technology

Pirtobrutinib has received an FDA orphan drug designation for CLL, and given the true orphan status of RT, regulatory approval with an RT-specific label could be pursued swiftly with this data. GlobalData’s consensus analyst forecast database projects peak sales for pirtobrutinib to reach $892 million by 2028, and $4.8